Metabolic dysfunction and alcohol associated liver disease
MONDO:0957896A steatotic liver disease characterized by at least one of the five cardiometabolic risk factors for MASLD and alcohol consumption of 140-350g/week (females) or 210-420g/week (males). This disease is distinguished from MASLD by increased alcohol consumption and from ALD by the evidence of one or more of the MASLD cardiometabolic risk factors.
10 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug aims to shrink liver fat and prevent scarring in fatty liver disease
Disease control OngoingThis Phase II trial tests an injection called DR10624 in 110 adults with fatty liver disease (MASLD) who are at high risk of liver fibrosis (scarring). The study is split into two parts: Part 1 checks if the drug reduces liver fat and fibrosis risk, while Part 2 focuses on safety…
Phase: PHASE2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
AI spots hidden liver disease in routine scans
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether an AI system can help doctors identify patients with fatty liver disease who need specialist care. About 8,000 adults getting routine CT scans will have their images analyzed by AI to flag those at risk. The goal is to see if AI can improve detection and …
Phase: NA • Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Major study aims to spare patients painful liver biopsies
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1,689 adults with fatty liver disease (MASLD) or MASLD with increased alcohol intake (MetALD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression. The goal is to reduce the need for liver biopsies in future research and …
Sponsor: HRI-MAIL-NIT • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC